Latest developments and emerging treatment options in the management of stomach cancer.

Cancer Manag Res · 2011 · PMC3139486 · PMID 21792334

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The authors showed a trend favoring the docetaxel + cisplatin + 5-FU combination in terms of response rate and median time to progression compared with ECF.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.